E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate in patients with advanced follicular lymphoma the benefit of maintenance therapy with rituximab after induction of response with chemotherapy plus rituximab in comparison with no maintenance therapy |
|
E.2.2 | Secondary objectives of the trial |
To evaluate response rates, event driven survival endpoints (Event Free Survival, Progression Free Survival, Overall Survival) and quality of life of four different chemotherapy regimens combined with rituximab, with or without maintenance with rituximab, for first line treatment of advanced stage follicular lymphoma. |
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Histologically confirmed follicular lymphoma grade 1, 2 or 3a (biopsy ≤ 4 months). - Patients previously untreated. - Bulky disease at study entry according to the GELF criteria: - Age must be > 18 years. - Performance status < 2 on the ECOG scale (see appendix E1). - Adequate hematological function (unless those abnormalities are related to lymphoma extension) within 28 days prior to registration, including: • Hemoglobin ≥ 8.0 g/dL (5.0 mmol/L) • Absolute neutrophil count (ANC) ≥ 1.5 109/L • Platelet count ≥ 100 109/L - Women are not breast feeding, are using effective contraception, are not pregnant and agree not to become pregnant during participation in the trial and during the 12 months thereafter. Men agree not to father a child during participation in the trial and during the 12 months thereafter. - Having previously signed a written informed consent form.
|
|
E.4 | Principal exclusion criteria |
- Transformation to high-grade lymphoma (secondary to “low-grade” follicular lymphoma). - Grade 3b follicular lymphoma. - Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningitis). - Patients regularly taking corticosteroids during the last 4 weeks, unless administered at a dose equivalent to < 20 mg/day prednisone. - Patients with prior or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer. - Major surgery (excluding lymph node biopsy) within 28 days prior to registration. - Poor renal function: Serum creatinine > 2.0 mg/dL (197 μmol/L), - Poor hepatic function: total bilirubin > 2.0 mg/dL (34 μmol/L), AST (SGT) > 3 x the upper limit of normal unless these abnormalities are related to lymphoma. - Known HIV infection or active HBV or HCV infection ≤ 4 weeks at registration. - Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease). Judgment is up to the investigator. - Life expectancy < 6 months - Known sensitivity or allergy to murine products - Treatment within a clinical trial within 30 days prior to trial entry - Any other co-existing medical or psychological condition that will preclude participation in the study or compromise ability to give informed consent.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Event Free Survival (EFS) defined as the time from randomization to progression, relapse, death from any cause, or requirement of a new treatment whatever the reason. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject undergoing the trial |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 6 |